Andrew P. Mazar
Andrew P. Mazar, Escondido, CA US
Patent application number | Description | Published |
---|---|---|
20090143303 | Anti-invasive and anti-angiogenic compositions - A peptide compound having the sequence Lys-Pro-Ser-Ser-Pro-Pro-Glu-Glu [SEQ ID NO:2] or a substitution variant, addition variant or other chemical derivative thereof inhibits cell invasion, endothelial tube formation or angiogenesis in vitro. A number of substitution variants and addition variants of this peptide, preferably capped at the N- and C-termini, as well as peptidomimetic derivatives, are useful for treating diseases and conditions mediated by undesired and uncontrolled cell invasion and/or angiogenesis. Pharmaceutical compositions comprising the above peptides and derivatives are administered to subjects in need of such treatment in a dosage sufficient to inhibit invasion and/or angiogenesis. The disclosed compositions and methods are particularly useful for suppressing the growth and metastasis of tumors. | 06-04-2009 |
20110065640 | ANTI-INVASIVE AND ANTI-ANGIOGENIC COMPOSITIONS - A peptide compound having the sequence Lys-Pro-Ser-Ser-Pro-Pro-Glu-Glu [SEQ ID NO:2] or a substitution variant, addition variant or other chemical derivative thereof inhibits cell invasion, endothelial tube formation or angiogenesis in vitro. A number of substitution variants and addition variants of this peptide, preferably capped at the N- and C-termini, as well as peptidomimetic derivates, are useful for treating diseases and conditions mediated by undesired and uncontrolled cell invasion and/or angiogenesis. Pharmaceutical compositions comprising the above peptides and derivatives are administered to subjects in need of such treatment in a dosage sufficient to inhibit invasion and/or angiogenesis. The disclosed compositions and methods are particularly useful for suppressing the growth and metastasis of tumors. | 03-17-2011 |
Andrew P. Mazar, San Diego, CA US
Patent application number | Description | Published |
---|---|---|
20080199476 | Urokinase-type plasminogen activator receptor epitope, monoclonal antibodies derived therefrom and methods of use thereof - The present invention relates to antibodies, and antigen-binding fragments thereof, specific for urokinase-type plasminogen activator receptor (uPAR) and uses thereof for the treatment or prevention of cancer. In particular, the antibodies of the invention are specific for a particular epitope on uPAR. These antibodies interfere with uPAR signaling. Such antibodies are used in diagnostic and therapeutic methods, particularly against cancer. | 08-21-2008 |
20080261892 | Acid Addition Salts of Ac-Phscn-Nh2 - Acid addition salts of Ac—PHSCN—NH | 10-23-2008 |
20090180952 | Ligands binding the complex of urokinase-type plasminogen activator (uppa) and its receptor (upar) that inhibit downstream upar interactions: identification and use in diagnosis or therapy - Antibodies or other ligands specific for the binary uPA-uPAR complexes, for ternary complexes comprising uPA-uPAR and for complexes of uPAR and proteins other than uPA such as integrins inhibit the interaction of uPA and uPAR with additional molecules with which the complexed interact. Such antibodies or other ligands are used in diagnostic and therapeutic methods, particularly against cancer. | 07-16-2009 |
20090312243 | TREATMENT OF INFLAMMATORY BOWEL DISEASE (IBD) WITH ANTI-ANGIOGENIC COMPOUNDS - Inhibitors of angiogenesis are disclosed as being useful therapeutics for treating various aspects of inflammatory bowel disease, in particular Crohn's Disease. A method for decreasing the magnitude of intestinal inflammation or inflammatory infiltrate in bowel tissue, a method for lowering systemic or gut-associated levels of a proinflammatory cytokine in a subject, a method for reducing microvessel density in fixed bowel tissue sections and a method for treating an inflammatory bowel disease are disclosed. Preferred agents to achieve the foregoing are pentapeptides that include Pro-His-Ser-Cys-Asn (SEQ ID NO:1) and variants or derivatives thereof. | 12-17-2009 |
20110151022 | THIOTUNGSTATE ANALOGUES AND USES THEREOF - The current invention provides novel thiotungstate derivatives, methods of making novel thiotungstate derivatives, pharmaceutical compositions of novel thiotungstate derivatives, methods of using novel thiotungstate derivatives to treat diseases associated with aberrant vascularization, copper metabolism disorders and obesity and methods of using pharmaceutical compositions of thiotungstate derivatives to treat diseases associated with aberrant vascularization, copper metabolism disorders, neurodegenerative disorders, obesity or NF-κB dysregulation. | 06-23-2011 |
Andrew P. Mazar, Highland Park, IL US
Patent application number | Description | Published |
---|---|---|
20090170123 | Identification of Novel Protein Targets on the Surface of Stressed Cells - The present invention in the field of biochemistry and medicine is directed to novel methods for identifying molecules, typically proteins, that move to the cell surface when cells are stimulated or stressed can act as receptors even thought they are not transmembrane molecules and normally originate in the cytosol. Such molecules are useful targets for development of agents that can image or treat tumors or other pathologies. Methods to detect or identify such proteins that have translocated to the cell surface when cells are stressed by an angiogenic environment, environmental stresses, the stimulation of cell proliferation and differentiation, or after exposure to certain drugs such as cancer chemotherapeutics, are disclosed. | 07-02-2009 |
20090264628 | CRYSTAL STRUCTURE OF HUMAN UROKINASE PLASMINOGEN ACTIVATOR AMINO TEMINAL FRAGMENT BOUND TO ITS RECEPTOR - Urokinase-type plasminogen activator (uPA) binds its cellular receptor (uPAR) with high affinity, thus localizing the generation of plasmin from plasminogen on the surface of a variety of cells. Disclosed herein is the structure of suPAR (uPAR | 10-22-2009 |